Global Mucopolysaccharidosis Therapeutics Market Research Report 2024(Status and Outlook)
Report Overview:
MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
The Global Mucopolysaccharidosis Therapeutics Market Size was estimated at USD 2508.27 million in 2023 and is projected to reach USD 3399.92 million by 2029, exhibiting a CAGR of 5.20% during the forecast period.
This report provides a deep insight into the global Mucopolysaccharidosis Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Mucopolysaccharidosis Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Mucopolysaccharidosis Therapeutics market in any manner.
Global Mucopolysaccharidosis Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen
REGENXBIO Inc.
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics Inc.
Ultragenyx Pharmaceutical
Genzyme Corporation
Market Segmentation (by Type)
Intravenous
Intracerebroventricular (ICV)
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Mucopolysaccharidosis Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
The Global Mucopolysaccharidosis Therapeutics Market Size was estimated at USD 2508.27 million in 2023 and is projected to reach USD 3399.92 million by 2029, exhibiting a CAGR of 5.20% during the forecast period.
This report provides a deep insight into the global Mucopolysaccharidosis Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Mucopolysaccharidosis Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Mucopolysaccharidosis Therapeutics market in any manner.
Global Mucopolysaccharidosis Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen
REGENXBIO Inc.
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics Inc.
Ultragenyx Pharmaceutical
Genzyme Corporation
Market Segmentation (by Type)
Intravenous
Intracerebroventricular (ICV)
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Mucopolysaccharidosis Therapeutics Market
- Overview of the regional outlook of the Mucopolysaccharidosis Therapeutics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Mucopolysaccharidosis Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Mucopolysaccharidosis Therapeutics
1.2 Key Market Segments
1.2.1 Mucopolysaccharidosis Therapeutics Segment by Type
1.2.2 Mucopolysaccharidosis Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Mucopolysaccharidosis Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Mucopolysaccharidosis Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Mucopolysaccharidosis Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Mucopolysaccharidosis Therapeutics Sales Sites, Area Served, Product Type
3.6 Mucopolysaccharidosis Therapeutics Market Competitive Situation and Trends
3.6.1 Mucopolysaccharidosis Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Mucopolysaccharidosis Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Mucopolysaccharidosis Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Mucopolysaccharidosis Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Mucopolysaccharidosis Therapeutics Price by Type (2019-2024)
7 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Mucopolysaccharidosis Therapeutics Market Sales by Application (2019-2024)
7.3 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
8 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY REGION
8.1 Global Mucopolysaccharidosis Therapeutics Sales by Region
8.1.1 Global Mucopolysaccharidosis Therapeutics Sales by Region
8.1.2 Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Mucopolysaccharidosis Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Mucopolysaccharidosis Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Mucopolysaccharidosis Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Mucopolysaccharidosis Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Mucopolysaccharidosis Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Shire (Takeda Pharmaceutical Company Limited)
9.1.1 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Basic Information
9.1.2 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Overview
9.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Market Performance
9.1.4 Shire (Takeda Pharmaceutical Company Limited) Business Overview
9.1.5 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics SWOT Analysis
9.1.6 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
9.2 Denali Therapeutics
9.2.1 Denali Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
9.2.2 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
9.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Market Performance
9.2.4 Denali Therapeutics Business Overview
9.2.5 Denali Therapeutics Mucopolysaccharidosis Therapeutics SWOT Analysis
9.2.6 Denali Therapeutics Recent Developments
9.3 ArmaGen
9.3.1 ArmaGen Mucopolysaccharidosis Therapeutics Basic Information
9.3.2 ArmaGen Mucopolysaccharidosis Therapeutics Product Overview
9.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Product Market Performance
9.3.4 ArmaGen Mucopolysaccharidosis Therapeutics SWOT Analysis
9.3.5 ArmaGen Business Overview
9.3.6 ArmaGen Recent Developments
9.4 REGENXBIO Inc.
9.4.1 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Basic Information
9.4.2 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Overview
9.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Market Performance
9.4.4 REGENXBIO Inc. Business Overview
9.4.5 REGENXBIO Inc. Recent Developments
9.5 Sangamo Therapeutics
9.5.1 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
9.5.2 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
9.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Market Performance
9.5.4 Sangamo Therapeutics Business Overview
9.5.5 Sangamo Therapeutics Recent Developments
9.6 BioMarin
9.6.1 BioMarin Mucopolysaccharidosis Therapeutics Basic Information
9.6.2 BioMarin Mucopolysaccharidosis Therapeutics Product Overview
9.6.3 BioMarin Mucopolysaccharidosis Therapeutics Product Market Performance
9.6.4 BioMarin Business Overview
9.6.5 BioMarin Recent Developments
9.7 Lysogene
9.7.1 Lysogene Mucopolysaccharidosis Therapeutics Basic Information
9.7.2 Lysogene Mucopolysaccharidosis Therapeutics Product Overview
9.7.3 Lysogene Mucopolysaccharidosis Therapeutics Product Market Performance
9.7.4 Lysogene Business Overview
9.7.5 Lysogene Recent Developments
9.8 Abeona Therapeutics Inc.
9.8.1 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Basic Information
9.8.2 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Overview
9.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Market Performance
9.8.4 Abeona Therapeutics Inc. Business Overview
9.8.5 Abeona Therapeutics Inc. Recent Developments
9.9 Ultragenyx Pharmaceutical
9.9.1 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Basic Information
9.9.2 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Overview
9.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Market Performance
9.9.4 Ultragenyx Pharmaceutical Business Overview
9.9.5 Ultragenyx Pharmaceutical Recent Developments
9.10 Genzyme Corporation
9.10.1 Genzyme Corporation Mucopolysaccharidosis Therapeutics Basic Information
9.10.2 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Overview
9.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Market Performance
9.10.4 Genzyme Corporation Business Overview
9.10.5 Genzyme Corporation Recent Developments
10 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET FORECAST BY REGION
10.1 Global Mucopolysaccharidosis Therapeutics Market Size Forecast
10.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Mucopolysaccharidosis Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Mucopolysaccharidosis Therapeutics Market Size Forecast by Region
10.2.4 South America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Mucopolysaccharidosis Therapeutics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Mucopolysaccharidosis Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Mucopolysaccharidosis Therapeutics by Type (2025-2030)
11.1.2 Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Mucopolysaccharidosis Therapeutics by Type (2025-2030)
11.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) Forecast by Application
11.2.2 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Mucopolysaccharidosis Therapeutics
1.2 Key Market Segments
1.2.1 Mucopolysaccharidosis Therapeutics Segment by Type
1.2.2 Mucopolysaccharidosis Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Mucopolysaccharidosis Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Mucopolysaccharidosis Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Mucopolysaccharidosis Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Mucopolysaccharidosis Therapeutics Sales Sites, Area Served, Product Type
3.6 Mucopolysaccharidosis Therapeutics Market Competitive Situation and Trends
3.6.1 Mucopolysaccharidosis Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Mucopolysaccharidosis Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Mucopolysaccharidosis Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Mucopolysaccharidosis Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Mucopolysaccharidosis Therapeutics Price by Type (2019-2024)
7 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Mucopolysaccharidosis Therapeutics Market Sales by Application (2019-2024)
7.3 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
8 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SEGMENTATION BY REGION
8.1 Global Mucopolysaccharidosis Therapeutics Sales by Region
8.1.1 Global Mucopolysaccharidosis Therapeutics Sales by Region
8.1.2 Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Mucopolysaccharidosis Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Mucopolysaccharidosis Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Mucopolysaccharidosis Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Mucopolysaccharidosis Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Mucopolysaccharidosis Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Shire (Takeda Pharmaceutical Company Limited)
9.1.1 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Basic Information
9.1.2 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Overview
9.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Market Performance
9.1.4 Shire (Takeda Pharmaceutical Company Limited) Business Overview
9.1.5 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics SWOT Analysis
9.1.6 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
9.2 Denali Therapeutics
9.2.1 Denali Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
9.2.2 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
9.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Market Performance
9.2.4 Denali Therapeutics Business Overview
9.2.5 Denali Therapeutics Mucopolysaccharidosis Therapeutics SWOT Analysis
9.2.6 Denali Therapeutics Recent Developments
9.3 ArmaGen
9.3.1 ArmaGen Mucopolysaccharidosis Therapeutics Basic Information
9.3.2 ArmaGen Mucopolysaccharidosis Therapeutics Product Overview
9.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Product Market Performance
9.3.4 ArmaGen Mucopolysaccharidosis Therapeutics SWOT Analysis
9.3.5 ArmaGen Business Overview
9.3.6 ArmaGen Recent Developments
9.4 REGENXBIO Inc.
9.4.1 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Basic Information
9.4.2 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Overview
9.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Market Performance
9.4.4 REGENXBIO Inc. Business Overview
9.4.5 REGENXBIO Inc. Recent Developments
9.5 Sangamo Therapeutics
9.5.1 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
9.5.2 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
9.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Market Performance
9.5.4 Sangamo Therapeutics Business Overview
9.5.5 Sangamo Therapeutics Recent Developments
9.6 BioMarin
9.6.1 BioMarin Mucopolysaccharidosis Therapeutics Basic Information
9.6.2 BioMarin Mucopolysaccharidosis Therapeutics Product Overview
9.6.3 BioMarin Mucopolysaccharidosis Therapeutics Product Market Performance
9.6.4 BioMarin Business Overview
9.6.5 BioMarin Recent Developments
9.7 Lysogene
9.7.1 Lysogene Mucopolysaccharidosis Therapeutics Basic Information
9.7.2 Lysogene Mucopolysaccharidosis Therapeutics Product Overview
9.7.3 Lysogene Mucopolysaccharidosis Therapeutics Product Market Performance
9.7.4 Lysogene Business Overview
9.7.5 Lysogene Recent Developments
9.8 Abeona Therapeutics Inc.
9.8.1 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Basic Information
9.8.2 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Overview
9.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Market Performance
9.8.4 Abeona Therapeutics Inc. Business Overview
9.8.5 Abeona Therapeutics Inc. Recent Developments
9.9 Ultragenyx Pharmaceutical
9.9.1 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Basic Information
9.9.2 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Overview
9.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Market Performance
9.9.4 Ultragenyx Pharmaceutical Business Overview
9.9.5 Ultragenyx Pharmaceutical Recent Developments
9.10 Genzyme Corporation
9.10.1 Genzyme Corporation Mucopolysaccharidosis Therapeutics Basic Information
9.10.2 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Overview
9.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Market Performance
9.10.4 Genzyme Corporation Business Overview
9.10.5 Genzyme Corporation Recent Developments
10 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET FORECAST BY REGION
10.1 Global Mucopolysaccharidosis Therapeutics Market Size Forecast
10.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Mucopolysaccharidosis Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Mucopolysaccharidosis Therapeutics Market Size Forecast by Region
10.2.4 South America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Mucopolysaccharidosis Therapeutics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Mucopolysaccharidosis Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Mucopolysaccharidosis Therapeutics by Type (2025-2030)
11.1.2 Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Mucopolysaccharidosis Therapeutics by Type (2025-2030)
11.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) Forecast by Application
11.2.2 Global Mucopolysaccharidosis Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Mucopolysaccharidosis Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Mucopolysaccharidosis Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Mucopolysaccharidosis Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Table 10. Global Market Mucopolysaccharidosis Therapeutics Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Mucopolysaccharidosis Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Mucopolysaccharidosis Therapeutics Product Type
Table 13. Global Mucopolysaccharidosis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Mucopolysaccharidosis Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Mucopolysaccharidosis Therapeutics Market Challenges
Table 22. Global Mucopolysaccharidosis Therapeutics Sales by Type (Kilotons)
Table 23. Global Mucopolysaccharidosis Therapeutics Market Size by Type (M USD)
Table 24. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Type (2019-2024)
Table 25. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Mucopolysaccharidosis Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Mucopolysaccharidosis Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Mucopolysaccharidosis Therapeutics Price (USD/Ton) by Type (2019-2024)
Table 29. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Application
Table 30. Global Mucopolysaccharidosis Therapeutics Market Size by Application
Table 31. Global Mucopolysaccharidosis Therapeutics Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Mucopolysaccharidosis Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Mucopolysaccharidosis Therapeutics Market Share by Application (2019-2024)
Table 35. Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 43. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Basic Information
Table 44. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Overview
Table 45. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 47. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 48. Shire (Takeda Pharmaceutical Company Limited) Recent Developments
Table 49. Denali Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
Table 50. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
Table 51. Denali Therapeutics Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Denali Therapeutics Business Overview
Table 53. Denali Therapeutics Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 54. Denali Therapeutics Recent Developments
Table 55. ArmaGen Mucopolysaccharidosis Therapeutics Basic Information
Table 56. ArmaGen Mucopolysaccharidosis Therapeutics Product Overview
Table 57. ArmaGen Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. ArmaGen Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 59. ArmaGen Business Overview
Table 60. ArmaGen Recent Developments
Table 61. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Basic Information
Table 62. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Overview
Table 63. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. REGENXBIO Inc. Business Overview
Table 65. REGENXBIO Inc. Recent Developments
Table 66. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
Table 67. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
Table 68. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sangamo Therapeutics Business Overview
Table 70. Sangamo Therapeutics Recent Developments
Table 71. BioMarin Mucopolysaccharidosis Therapeutics Basic Information
Table 72. BioMarin Mucopolysaccharidosis Therapeutics Product Overview
Table 73. BioMarin Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. BioMarin Business Overview
Table 75. BioMarin Recent Developments
Table 76. Lysogene Mucopolysaccharidosis Therapeutics Basic Information
Table 77. Lysogene Mucopolysaccharidosis Therapeutics Product Overview
Table 78. Lysogene Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Lysogene Business Overview
Table 80. Lysogene Recent Developments
Table 81. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Basic Information
Table 82. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Overview
Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Abeona Therapeutics Inc. Business Overview
Table 85. Abeona Therapeutics Inc. Recent Developments
Table 86. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Basic Information
Table 87. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Overview
Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Ultragenyx Pharmaceutical Business Overview
Table 90. Ultragenyx Pharmaceutical Recent Developments
Table 91. Genzyme Corporation Mucopolysaccharidosis Therapeutics Basic Information
Table 92. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Overview
Table 93. Genzyme Corporation Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Genzyme Corporation Business Overview
Table 95. Genzyme Corporation Recent Developments
Table 96. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Mucopolysaccharidosis Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Mucopolysaccharidosis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Mucopolysaccharidosis Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Mucopolysaccharidosis Therapeutics Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Mucopolysaccharidosis Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Mucopolysaccharidosis Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Mucopolysaccharidosis Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Table 10. Global Market Mucopolysaccharidosis Therapeutics Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Mucopolysaccharidosis Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Mucopolysaccharidosis Therapeutics Product Type
Table 13. Global Mucopolysaccharidosis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Mucopolysaccharidosis Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Mucopolysaccharidosis Therapeutics Market Challenges
Table 22. Global Mucopolysaccharidosis Therapeutics Sales by Type (Kilotons)
Table 23. Global Mucopolysaccharidosis Therapeutics Market Size by Type (M USD)
Table 24. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Type (2019-2024)
Table 25. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Mucopolysaccharidosis Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Mucopolysaccharidosis Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Mucopolysaccharidosis Therapeutics Price (USD/Ton) by Type (2019-2024)
Table 29. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) by Application
Table 30. Global Mucopolysaccharidosis Therapeutics Market Size by Application
Table 31. Global Mucopolysaccharidosis Therapeutics Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Mucopolysaccharidosis Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Mucopolysaccharidosis Therapeutics Market Share by Application (2019-2024)
Table 35. Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Mucopolysaccharidosis Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 43. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Basic Information
Table 44. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Overview
Table 45. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 47. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 48. Shire (Takeda Pharmaceutical Company Limited) Recent Developments
Table 49. Denali Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
Table 50. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
Table 51. Denali Therapeutics Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Denali Therapeutics Business Overview
Table 53. Denali Therapeutics Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 54. Denali Therapeutics Recent Developments
Table 55. ArmaGen Mucopolysaccharidosis Therapeutics Basic Information
Table 56. ArmaGen Mucopolysaccharidosis Therapeutics Product Overview
Table 57. ArmaGen Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. ArmaGen Mucopolysaccharidosis Therapeutics SWOT Analysis
Table 59. ArmaGen Business Overview
Table 60. ArmaGen Recent Developments
Table 61. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Basic Information
Table 62. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Overview
Table 63. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. REGENXBIO Inc. Business Overview
Table 65. REGENXBIO Inc. Recent Developments
Table 66. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Basic Information
Table 67. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Overview
Table 68. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sangamo Therapeutics Business Overview
Table 70. Sangamo Therapeutics Recent Developments
Table 71. BioMarin Mucopolysaccharidosis Therapeutics Basic Information
Table 72. BioMarin Mucopolysaccharidosis Therapeutics Product Overview
Table 73. BioMarin Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. BioMarin Business Overview
Table 75. BioMarin Recent Developments
Table 76. Lysogene Mucopolysaccharidosis Therapeutics Basic Information
Table 77. Lysogene Mucopolysaccharidosis Therapeutics Product Overview
Table 78. Lysogene Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Lysogene Business Overview
Table 80. Lysogene Recent Developments
Table 81. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Basic Information
Table 82. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Overview
Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Abeona Therapeutics Inc. Business Overview
Table 85. Abeona Therapeutics Inc. Recent Developments
Table 86. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Basic Information
Table 87. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Overview
Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Ultragenyx Pharmaceutical Business Overview
Table 90. Ultragenyx Pharmaceutical Recent Developments
Table 91. Genzyme Corporation Mucopolysaccharidosis Therapeutics Basic Information
Table 92. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Overview
Table 93. Genzyme Corporation Mucopolysaccharidosis Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Genzyme Corporation Business Overview
Table 95. Genzyme Corporation Recent Developments
Table 96. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Mucopolysaccharidosis Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Mucopolysaccharidosis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Mucopolysaccharidosis Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Mucopolysaccharidosis Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Mucopolysaccharidosis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Mucopolysaccharidosis Therapeutics Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Mucopolysaccharidosis Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Mucopolysaccharidosis Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Mucopolysaccharidosis Therapeutics Market Size by Country (M USD)
Figure 11. Mucopolysaccharidosis Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Mucopolysaccharidosis Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Mucopolysaccharidosis Therapeutics Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Mucopolysaccharidosis Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Mucopolysaccharidosis Therapeutics Market Share by Type
Figure 18. Sales Market Share of Mucopolysaccharidosis Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Mucopolysaccharidosis Therapeutics by Type in 2023
Figure 20. Market Size Share of Mucopolysaccharidosis Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Mucopolysaccharidosis Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Mucopolysaccharidosis Therapeutics Market Share by Application
Figure 24. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Mucopolysaccharidosis Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Mucopolysaccharidosis Therapeutics Market Share by Application in 2023
Figure 28. Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Mucopolysaccharidosis Therapeutics Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Mucopolysaccharidosis Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Mucopolysaccharidosis Therapeutics Sales Market Share by Region in 2023
Figure 44. China Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 50. South America Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Mucopolysaccharidosis Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Mucopolysaccharidosis Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Mucopolysaccharidosis Therapeutics Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Mucopolysaccharidosis Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Mucopolysaccharidosis Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Mucopolysaccharidosis Therapeutics Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Mucopolysaccharidosis Therapeutics Market Size by Country (M USD)
Figure 11. Mucopolysaccharidosis Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Mucopolysaccharidosis Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Mucopolysaccharidosis Therapeutics Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Mucopolysaccharidosis Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Mucopolysaccharidosis Therapeutics Market Share by Type
Figure 18. Sales Market Share of Mucopolysaccharidosis Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Mucopolysaccharidosis Therapeutics by Type in 2023
Figure 20. Market Size Share of Mucopolysaccharidosis Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Mucopolysaccharidosis Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Mucopolysaccharidosis Therapeutics Market Share by Application
Figure 24. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Mucopolysaccharidosis Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Mucopolysaccharidosis Therapeutics Market Share by Application in 2023
Figure 28. Global Mucopolysaccharidosis Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Mucopolysaccharidosis Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Mucopolysaccharidosis Therapeutics Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Mucopolysaccharidosis Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Mucopolysaccharidosis Therapeutics Sales Market Share by Region in 2023
Figure 44. China Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 50. South America Mucopolysaccharidosis Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Mucopolysaccharidosis Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Mucopolysaccharidosis Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Mucopolysaccharidosis Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Mucopolysaccharidosis Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Mucopolysaccharidosis Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Mucopolysaccharidosis Therapeutics Market Share Forecast by Application (2025-2030)
